Neurim Pharmaceuticals Ltd.

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Private

Established: 1991-01-01

Employees: 11

Market Cap: -

Website: http://www.neurim.com

Clinical Trials

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Phase 2

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: Piromelatine 20 mg
Drug: Placebo

First Posted Date: 2022-03-04

Last Posted Date: 2024-06-21

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 225

Registration Number: NCT05267535

Locations: 🇨🇦
OCT Research ULC (dba Okanagan Clinical Trials), Kelowna, Canada
🇺🇸
ATP Clinical Research, Costa Mesa, California, United States
🇺🇸
Pacific Research Network, LLC, San Diego, California, United States

and more 33 locations

Efficacy and Safety of Slenyto for Insomnia in Children With ASD

Phase 3

Withdrawn

Conditions: Autism Spectrum Disorder

Interventions: Drug: Melatonin
Drug: Placebo

First Posted Date: 2020-01-18

Last Posted Date: 2021-03-12

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Registration Number: NCT04233502

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Piromelatine
Drug: Placebo

First Posted Date: 2015-11-25

Last Posted Date: 2024-07-05

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 371

Registration Number: NCT02615002

Locations: 🇺🇸
Biomed Research Institute, Miami, Florida, United States
🇺🇸
Advanced Clinical research Network, Miami, Florida, United States
🇺🇸
Alliance for Research, Long Beach, California, United States

and more 53 locations

Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Phase 3

Completed

Conditions: Sleep Disorders

Interventions: Drug: Circadin 2/5/10 mg
Drug: Placebo

First Posted Date: 2013-07-24

Last Posted Date: 2024-04-23

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 125

Registration Number: NCT01906866

Locations: 🇺🇸
AMR Baber research INC, Naperville, Illinois, United States
🇺🇸
Lake Mary Pediatrics, Orange City, Florida, United States
🇺🇸
Child Neurology Specialists/ CRCN, Henderson, Nevada, United States

and more 25 locations

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Phase 1

Completed

Conditions: Sleep Problems

Interventions: Drug: Circadin 10 mg
Drug: Circadin 2 mg

First Posted Date: 2013-07-19

Last Posted Date: 2014-04-04

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 16

Registration Number: NCT01903681

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Phase 2

Completed

Conditions: Primary Insomnia

Interventions: Drug: Neu-P11

First Posted Date: 2011-12-12

Last Posted Date: 2018-06-06

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 137

Registration Number: NCT01489969

Locations: 🇺🇸
Chicago Research Center, Chicago, Illinois, United States
🇺🇸
Miami research Associates, South Miami, Florida, United States
🇺🇸
Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States

and more 6 locations

Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects

Phase 4

Completed

Conditions: Postural Instability

Interventions: Drug: Circadin (R) 2 mg
Drug: Stilnox (R) 10 mg
Drug: Placebo

First Posted Date: 2011-01-21

Last Posted Date: 2011-12-13

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 26

Registration Number: NCT01280734

Locations: 🇫🇷
Forenap, Rouffach, France

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: Neu-P11
Drug: Neu-P11 placebo

First Posted Date: 2010-04-30

Last Posted Date: 2011-04-07

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT01114126

Locations: 🇫🇷
Centre hospitallier de Rouffach, Rouffach, France

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Phase 2

Completed

Conditions: Non-24 Hour Sleep-Wake Disorder
Blindness

Interventions: Drug: melatonin (Circadin)
Drug: placebo

First Posted Date: 2009-09-04

Last Posted Date: 2009-09-09

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 13

Registration Number: NCT00972075

Locations: 🇺🇸
Sleep Disorders Center of Atlanta, Atlanta, Georgia, United States
🇺🇸
Clinlabs, Inc., New York, New York, United States

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Phase 2

Completed

Conditions: Sleep Disorder
Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Circadin

First Posted Date: 2009-07-16

Last Posted Date: 2018-06-01

Lead Sponsor: Neurim Pharmaceuticals Ltd.

Target Recruit Count: 73

Registration Number: NCT00940589

Locations: 🇺🇸
Meridien Research, Saint Petersburg, Florida, United States
🇺🇸
Exodon LLC, Mount Arlington, New Jersey, United States
🇮🇱
Merchav clinics, Tel-Aviv, Israel

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy